These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 311514

  • 1. [Immune profile in patients with Hodgkin's disease in long-term remission after cytostatic chemotherapy].
    Nagel GA, Pietra CD, Hartmann D, Rosenthal M, Albrecht R, Obrist R, Obrecht P.
    Schweiz Med Wochenschr; 1979 Jan 13; 109(2):45-51. PubMed ID: 311514
    [Abstract] [Full Text] [Related]

  • 2. Persisting lymphocyte deficiences during remission in Hodgkin's disease.
    Björkholm M, Holm G, Mellstedt H.
    Clin Exp Immunol; 1977 Jun 13; 28(3):389-93. PubMed ID: 302164
    [Abstract] [Full Text] [Related]

  • 3. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM, Bigel P, Oberling F, Mayer S.
    Pathol Biol (Paris); 1978 Jun 13; 26(3-4):159-62. PubMed ID: 355984
    [Abstract] [Full Text] [Related]

  • 4. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM, Bigel P, Oberling F, Mayer S.
    Sem Hop; 1978 Jun 13; 54(37-40):1155-8. PubMed ID: 217096
    [Abstract] [Full Text] [Related]

  • 5. Immunological study of patients with Hodgkin's disease in long-lasting not-maintained complete remission.
    Gobbi M, Fiacchini M, Tomasini I, Ruggero D, Lauria F, Tura S.
    Boll Ist Sieroter Milan; 1977 Mar 31; 56(2):144-51. PubMed ID: 326273
    [Abstract] [Full Text] [Related]

  • 6. Quantitative study of T and B lymphocytes in Hodgkin's disease.
    Bensa JC, Micouin C, Schaerer R, Sotto JJ, Hollard D.
    Biomedicine; 1977 Apr 31; 26(2):137-44. PubMed ID: 326312
    [Abstract] [Full Text] [Related]

  • 7. [Immunological data in the clinical evaluation of Hodgkin's diseases].
    Burchardt K.
    Z Gesamte Inn Med; 1981 Nov 01; 36(21):840. PubMed ID: 6977241
    [Abstract] [Full Text] [Related]

  • 8. Levamisole in the treatment of Hodgkin's disease.
    Berényi E, Kávai M, Szabolcsi M, Szegedi G.
    Acta Med Acad Sci Hung; 1979 Nov 01; 36(2):177-85. PubMed ID: 317549
    [Abstract] [Full Text] [Related]

  • 9. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
    Gajl-Peczalska KJ, Hansen JA, Bloomfield CD, Good RA.
    J Clin Invest; 1973 Dec 01; 52(12):3064-73. PubMed ID: 4201499
    [Abstract] [Full Text] [Related]

  • 10. [T- and B-lymphocyte changes in lymphogranulomatosis].
    Il'in NV, Vinokurova NA, Gershanovich ML, Letskiĭ VB.
    Vopr Onkol; 1979 Dec 01; 25(6):19-22. PubMed ID: 380155
    [Abstract] [Full Text] [Related]

  • 11. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
    Pluzańska A.
    Acta Haematol Pol; 1978 Dec 01; 9(1):37-44. PubMed ID: 307325
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect.
    Björkholm M, Holm G, Mellstedt H, Johansson B, Killander D, Sunblad R, Söderberg G.
    Scand J Haematol; 1978 Apr 01; 20(4):306-18. PubMed ID: 653310
    [Abstract] [Full Text] [Related]

  • 13. B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy.
    Gajl-Peczalska KJ, Bloomfield CD, Sosin H, Kersey JH.
    Clin Exp Immunol; 1976 Jan 01; 23(1):47-55. PubMed ID: 1083318
    [Abstract] [Full Text] [Related]

  • 14. Quantitation of immunocompetence in Hodgkin's disease.
    Faguet GB.
    J Clin Invest; 1975 Oct 01; 56(4):951-7. PubMed ID: 1159096
    [Abstract] [Full Text] [Related]

  • 15. [Effect of cytotoxic Hodgkin's serum on LIF activity of T- and B-lymphocytes].
    Chisesi T, Giacobbo M, Capnist T.
    Boll Ist Sieroter Milan; 1978 Sep 30; 57(4):428-33. PubMed ID: 310684
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Normal natural killer cell activity in Hodgkin's disease patients in remission.
    Douer D, Shaked N, Ramot B.
    Clin Exp Immunol; 1987 Sep 30; 69(3):660-7. PubMed ID: 3665188
    [Abstract] [Full Text] [Related]

  • 18. Management of advanced Hodgkin's disease in remission.
    Klener P, Hausner P, Donner L.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982 Sep 30; 109(2):213-7. PubMed ID: 6179821
    [Abstract] [Full Text] [Related]

  • 19. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
    Lang JM, Bigel P, Giron C, Faradji A, Oberling F, Mayer S.
    Nouv Presse Med; 1979 Nov 12; 8(44):3629-32. PubMed ID: 316521
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.